Press Releases Coherus BioSciences, Inc.

Equities

CHRS

US19249H1032

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
2.04 ^USD	+5.70%		-1.45%	-38.74%

04-24	Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting	CI
03-20	HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology Annual Meeting	04-25	AQ
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	04-24	GL
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting	04-08	GL
Coherus BioSciences: Q4 Earnings Snapshot	03-13	AQ
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update	03-13	GL
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	03-07	AQ
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024	03-05	GL
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024	03-05	AQ
Coherus Completes Divestiture of Ophthalmology Franchise	03-04	GL
Coherus Completes Divestiture of Ophthalmology Franchise	03-04	AQ
Coherus BioSciences Announces New Employment Inducement Grants	02-26	AQ
Coherus BioSciences Announces New Employment Inducement Grants	02-23	GL
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv	02-21	GL
Sandoz To Acquire CIMERLI From Coherus For $170 Million	02-15	AQ
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP	02-05	GL
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP	02-05	AQ
Sandoz announces agreement to acquire CIMERLI business from Coherus, strengthening position in US market	01-23	AQ
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal	01-22	GL
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal	01-22	AQ
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium	01-18	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Coherus BioSciences, Inc.

Equities

CHRS

US19249H1032

Press Releases

Filters